Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E7.81 EPS (ttm)4.89 Insider Own0.90% Shs Outstand179.01M Perf Week12.38%
Market Cap6.84B Forward P/E- EPS next Y-1.80 Insider Trans-14.50% Shs Float170.91M Perf Month-22.86%
Income902.70M PEG- EPS next Q-0.64 Inst Own94.80% Short Float9.25% Perf Quarter-36.91%
Sales1.37B P/S4.98 EPS this Y188.30% Inst Trans0.27% Short Ratio6.73 Perf Half Y-54.20%
Book/sh10.37 P/B3.69 EPS next Y-148.60% ROA53.60% Target Price82.00 Perf Year-14.91%
Cash/sh7.93 P/C4.82 EPS next 5Y-7.30% ROE78.60% 52W Range33.50 - 111.36 Perf YTD-35.98%
Dividend- P/FCF9.16 EPS past 5Y21.50% ROI56.40% 52W High-65.67% Beta2.69
Dividend %- Quick Ratio13.80 Sales past 5Y30.50% Gross Margin98.00% 52W Low14.12% ATR2.77
Employees509 Current Ratio13.90 Sales Q/Q-81.80% Oper. Margin55.60% RSI (14)41.08 Volatility6.53% 8.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-248.70% Profit Margin54.30% Rel Volume0.99 Prev Close38.19
ShortableYes LT Debt/Eq0.14 EarningsNov 07 AMC Payout0.00% Avg Volume2.35M Price38.23
Recom1.80 SMA200.10% SMA50-22.20% SMA200-43.99% Volume2,330,862 Change0.10%
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Sep-16-14Reiterated Brean Capital Buy $18 → $20
Nov-16-18 04:56PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline  NKTR GlobeNewswire
10:54AM  CLASS ACTION UPDATE for TRVN, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-14-18 09:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
02:50PM  Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics NKTR ACCESSWIRE
09:07AM  Can These 2 Battered Biotech Stocks Recover? Motley Fool
09:00AM  Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs PR Newswire
Nov-13-18 12:05PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, JT, COST, CWH, OZK, NKTR and AQUA GlobeNewswire
08:52AM  Nektar (NKTR) Catches Eye: Stock Jumps 8.7% Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-12-18 07:56PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Nektar, and Honeywell and Encourages Investors to Contact the Firm GlobeNewswire +8.73%
05:19PM  SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
04:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
04:23PM  Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy Investor's Business Daily
09:15AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 ACCESSWIRE
09:02AM  Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics GlobeNewswire
08:58AM  INVESTOR NOTICE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Amarin and Nektar Therapeutics ACCESSWIRE
Nov-11-18 10:07AM  CLASS ACTION UPDATE for APOG, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-10-18 09:26PM  Edited Transcript of NKTR earnings conference call or presentation 7-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 07:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR GlobeNewswire
06:52PM  Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Misled Shareholders According to Class Action Business Wire
06:15PM  Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
06:05PM  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR PR Newswire
02:40PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Nov-08-18 05:55PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, SFIX, CWH, HON, NKTR and SYF GlobeNewswire -6.96%
05:28PM  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics Business Wire
02:13PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm PR Newswire
01:50PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:11PM  SHAREHOLDER ALERT: MCHP COCP ABBV JT TRVN SFIX CWH HON ALGN NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
12:00PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
10:43AM  Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
09:57AM  East Bay biotech scores $42 million with potential quick-fix for heart trouble American City Business Journals
Nov-07-18 09:25PM  Nektar Therapeutics (NKTR) Q3 2018 Earnings Conference Call Transcript Motley Fool +5.18%
06:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR PR Newswire
05:05PM  Nektar: 3Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018 PR Newswire
03:25PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:45PM  CLASS ACTION UPDATE for COCP and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:23AM  Why Nektar Therapeutics Fell 36.5% in October Motley Fool
09:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 ACCESSWIRE
07:18AM  Nektar Therapeutics Q3 Earnings Outlook Benzinga
Nov-06-18 05:38PM  Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics GlobeNewswire -9.80%
05:23PM  Dow Gains 173 Points Because the Market Only Cares That Midterms Are Almost Over Barrons.com
04:45PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, HON, OZK and NKTR GlobeNewswire
04:30PM  Why Nektar Therapeutics Tumbled 10% Today Motley Fool
04:16PM  NKTR LOSS ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline NKTR GlobeNewswire
02:40PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:52AM  NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm Business Wire
08:30AM  New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers PR Newswire
08:00AM  Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting PR Newswire
Nov-05-18 06:49PM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
02:48PM  SHAREHOLDER ALERT: PVG USAT COCP JT GOOG OZK NKTR FIT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
02:29PM  Is Nektar Therapeutics (NASDAQ:NKTR) Worth US$39.05 Based On Intrinsic Value? Simply Wall St.
09:10AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 ACCESSWIRE
08:46AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
Nov-04-18 10:01AM  CLASS ACTION UPDATE for HON, DY, NKTR and FIT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR GlobeNewswire
Nov-02-18 02:58PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, GOOG, HON and NKTR GlobeNewswire
01:02PM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:25AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 ACCESSWIRE
10:20AM  NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm PR Newswire
Nov-01-18 12:25PM  SHAREHOLDER ALERT: SKX QRTEA MCHP TGTX ALNY HAS CPB TRVN HTHT NKTR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire +5.20%
12:15PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:10AM  Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Nektar Therapeutics (NKTR) Business Wire
Oct-31-18 07:30PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR) GlobeNewswire
04:15PM  CLASS ACTION UPDATE for TGTX, HAS and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:49PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
01:41PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR) and Encourages NKTR Investors to Contact the Firm GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 GlobeNewswire
Oct-30-18 08:52PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics NKTR Business Wire
07:19PM  Pomerantz Law Firm Announces the Filing of a Class Action against Nektar Therapeutics, Inc. and Certain Officers NKTR GlobeNewswire
05:00PM  Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets PR Newswire
Oct-24-18 08:37AM  Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options Zacks -7.32%
08:30AM  New Research Coverage Highlights Nektar Therapeutics, General Mills, Yelp, Zillow Group, Tutor Perini, and Hormel Foods Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-23-18 08:00AM  Todays Research Reports on Stocks to Watch: Tesaro and Nektar Therapeutics ACCESSWIRE
Oct-22-18 05:48PM  Why Nektar Therapeutics Crashed 17.2% Today Motley Fool -17.22%
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
07:30AM  Microsoft's typical worker makes $168K a year how that compares with Facebook, Google, PayPal, Box, Salesforce, Intel and other big Bay Area tech employers American City Business Journals
Oct-15-18 05:06PM  Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners American City Business Journals
Oct-12-18 07:08PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Oct-08-18 10:29AM  Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more American City Business Journals
Oct-05-18 08:14AM  Jim Cramer Gives His Opinion On Anheuser-Busch, Nektar, Walker & Dunlop And More Benzinga
06:56AM  These S&P 500 companies are expected to grow sales the most MarketWatch
Oct-04-18 06:50PM  Cramer's lightning round: Kratos' stock rally proved the haters wrong CNBC
02:40PM  INVESTOR ALERT: Investigation of Nektar Therapeutics Announced by Holzer & Holzer Business Wire
Oct-03-18 05:52PM  Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws PR Newswire
02:41PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR PR Newswire
Oct-02-18 07:30PM  Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI TheStreet.com
09:32AM  Did Bristol-Myers Squibb Make a Huge Mistake With Nektar? Motley Fool
08:38AM  The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis Zacks
08:00AM  Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics ACCESSWIRE
08:00AM  Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Oct-01-18 06:00PM  Nektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham PR Newswire -7.07%
10:28AM  5 Best Biotech Stocks to Buy In October Zacks
Sep-24-18 07:00AM  BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer GlobeNewswire
Sep-14-18 11:07AM  How Did Nektar Therapeuticss (NASDAQ:NKTR) 48.5% ROE Fare Against The Industry? Simply Wall St.
Sep-07-18 09:30AM  Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report? Zacks
Sep-06-18 02:25PM  Here's Why Nektar Therapeutics Jumped 26.4% in August Motley Fool
Sep-05-18 08:00AM  Today's Research Reports on Trending Tickers: Cronos Group and Nektar Therapeutics ACCESSWIRE
Aug-31-18 07:55AM  Market Trends Toward New Normal in Caesars Entertainment, Nektar Therapeutics, Boston Scientific, Apollo Commercial Real Estate Finance, Kellogg, and Foot Locker Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lingnau LutzDirectorSep 20Sale56.989,000512,82018,450Sep 21 07:32 PM
Ajer Jeffrey RobertDirectorSep 20Sale56.766,750383,13015,750Sep 21 07:29 PM
CHESS ROBERTDirectorSep 19Sale56.814,500255,645269,723Sep 21 07:31 PM
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM
WINGER DENNIS LDirectorAug 21Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 21Sale60.3015,000904,50042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Sale59.6215,000894,30042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 14Sale60.1517,1251,030,06942,750Aug 15 07:30 PM
WINGER DENNIS LDirectorAug 13Sale61.0417,1251,045,31059,875Aug 15 07:30 PM
ROBIN HOWARD WPresident & CEOJun 27Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 27Sale47.3943,3332,053,551224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Sale49.3643,3332,138,917224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Option Exercise10.6943,334463,240267,690Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Sale51.8243,3342,245,568224,356Jun 27 07:42 PM
GREER R SCOTTDirectorJun 06Option Exercise5.148,60044,204138,933Jun 06 07:42 PM
WHITFIELD ROY ADirectorJun 06Buy59.373,400201,860177,000Jun 07 07:40 PM
GREER R SCOTTDirectorJun 06Sale60.008,600516,000130,333Jun 06 07:42 PM
CHESS ROBERTDirectorJun 05Option Exercise14.2610,000142,600284,223Jun 07 07:39 PM
WHITFIELD ROY ADirectorJun 05Buy55.221,60088,352173,600Jun 07 07:40 PM
CHESS ROBERTDirectorJun 05Sale55.1610,000551,600274,223Jun 07 07:39 PM
GREER R SCOTTDirectorJun 04Option Exercise5.141,4007,196131,733Jun 06 07:42 PM
GREER R SCOTTDirectorJun 04Sale61.991,40086,786130,333Jun 06 07:42 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale83.393,576298,20365,281May 18 07:07 PM
ROBIN HOWARD WPresident & CEOMay 16Sale83.3912,7911,066,641224,356May 18 07:06 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale83.394,917410,029162,596May 18 07:05 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale83.394,941412,03094,798May 18 07:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale83.394,060338,56376,201May 18 07:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale83.393,435286,44563,959May 18 07:01 PM
CHESS ROBERTDirectorMay 03Option Exercise8.7925,000219,700289,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 03Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Option Exercise10.6930,000320,700129,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 03Sale82.8643,3333,590,572237,147May 03 08:42 PM
CHESS ROBERTDirectorMay 03Sale82.8025,0002,070,050274,223May 04 06:55 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Sale82.8630,0002,485,80099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Sale85.6330,0002,568,90099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Sale85.6343,3333,710,605237,147May 03 08:42 PM
ROBIN HOWARD WPresident & CEOMay 01Option Exercise10.6943,334463,240280,481May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Sale83.6530,0002,509,50099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 01Sale83.6543,3343,624,889237,147May 03 08:42 PM
WHITFIELD ROY ADirectorApr 17Option Exercise14.2630,000427,800172,000Apr 18 06:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Option Exercise10.6913,881148,38882,738Apr 18 06:03 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Sale101.4613,8811,408,36668,857Apr 18 06:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Option Exercise7.215023,61980,763Apr 12 06:05 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Sale105.6750253,04680,261Apr 12 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Option Exercise7.2149,500356,895116,894Apr 09 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Option Exercise7.219,49868,48189,759Apr 09 08:22 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Sale105.059,498997,76580,261Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Sale96.1349,5004,758,43567,394Apr 09 08:21 PM
CHESS ROBERTDirectorApr 06Option Exercise8.7925,000219,700289,223Apr 09 08:20 PM
GREER R SCOTTDirectorApr 06Option Exercise14.2630,000427,800160,333Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Option Exercise9.10110,5001,005,505177,894Apr 09 08:21 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Sale91.69110,50010,131,74567,394Apr 09 08:21 PM
GREER R SCOTTDirectorApr 06Sale92.2230,0002,766,600130,333Apr 09 08:22 PM
CHESS ROBERTDirectorApr 06Sale92.1425,0002,303,600274,223Apr 09 08:20 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise7.2120,000144,200100,261Apr 09 08:22 PM
Lingnau LutzDirectorApr 05Option Exercise9.2430,000277,20057,450Apr 09 08:23 PM
Lingnau LutzDirectorApr 05Sale101.7430,0003,052,20027,450Apr 09 08:23 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale101.7520,0002,035,00080,261Apr 09 08:22 PM
KUEBLER CHRISTOPHER ADirectorMar 07Option Exercise6.2437,400233,23677,900Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 07Sale97.4137,4003,643,13440,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 07Sale100.45100,14410,059,465167,513Mar 08 06:09 PM
KUEBLER CHRISTOPHER ADirectorMar 06Option Exercise5.142,60013,36443,100Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 06Sale100.302,600260,78040,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 06Sale98.29120,00011,794,800267,657Mar 08 06:09 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale82.942,545211,08268,857Feb 20 07:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale82.944,879404,664387,657Feb 20 07:09 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale82.9412,7881,060,637237,147Feb 20 07:10 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale82.942,875238,45380,261Feb 20 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale82.943,477288,38299,739Feb 20 07:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale82.942,426201,21267,394Feb 20 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerJan 31Option Exercise11.34120,0001,360,800392,536Feb 02 06:03 PM
ROBIN HOWARD WPresident & CEOJan 22Option Exercise11.3483,333944,996333,268Jan 24 06:01 PM
ROBIN HOWARD WPresident & CEOJan 22Sale75.8283,3336,318,308249,935Jan 24 06:01 PM
WINGER DENNIS LDirectorJan 04Option Exercise11.9733,750403,98877,000Jan 08 06:07 PM
KUEBLER CHRISTOPHER ADirectorJan 02Option Exercise14.2630,000427,80070,500Jan 04 06:01 PM
KUEBLER CHRISTOPHER ADirectorJan 02Sale58.6630,0001,759,80040,500Jan 04 06:01 PM
ROBIN HOWARD WPresident & CEODec 13Option Exercise11.3483,333944,996272,768Dec 15 06:00 PM
ROBIN HOWARD WPresident & CEODec 13Sale55.6983,3334,640,815189,435Dec 15 06:00 PM